Bank of America Merrill Lynch Health Care Conference 2019 Read more about Bank of America Merrill Lynch Health Care Conference 2019
bluebird bio Announces Investor Events in May Read more about bluebird bio Announces Investor Events in May
bluebird bio Reports First Quarter 2019 Financial Results and Highlights Operational Progress Read more about bluebird bio Reports First Quarter 2019 Financial Results and Highlights Operational Progress
Celgene Corporation and bluebird bio Announce Results from Ongoing Multicenter Phase 1 Study of bb2121 anti-BCMA CAR T Cell Therapy in Patients with Multiple Myeloma Published in New England Journal of Medicine Read more about Celgene Corporation and bluebird bio Announce Results from Ongoing Multicenter Phase 1 Study of bb2121 anti-BCMA CAR T Cell Therapy in Patients with Multiple Myeloma Published in New England Journal of Medicine
bluebird bio Appoints Joanne Smith-Farrell, Ph.D., to Chief Business Officer Read more about bluebird bio Appoints Joanne Smith-Farrell, Ph.D., to Chief Business Officer
bluebird bio Receives Positive Opinion from CHMP for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia (TDT) Who Do Not Have β0/β0 Genotype Read more about bluebird bio Receives Positive Opinion from CHMP for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia (TDT) Who Do Not Have β0/β0 Genotype
bluebird bio Statement on European Regulatory Status of LentiGlobin™ Read more about bluebird bio Statement on European Regulatory Status of LentiGlobin™
bluebird bio Opens State-of-the-Art Gene and Cell Therapy Manufacturing Facility in Durham, North Carolina Read more about bluebird bio Opens State-of-the-Art Gene and Cell Therapy Manufacturing Facility in Durham, North Carolina